Table A2:
Number of Studies (Design) | Risk of Bias | Inconsistency | Indirectness | Imprecision | Publication Bias | Upgrade Considerations | Quality |
---|---|---|---|---|---|---|---|
2 RCTs | No serious limitations | No serious limitations | No serious limitations | No serious limitations | Undetected Likely (−1) | Large magnitude of effect (+1) | ⊕⊕⊕⊕ High ⊕⊕⊕ Moderate |
40 observational case series | Serious limitations (−1) | Serious limitations (−1) | Serious limitations (−1) | Serious limitations (−1) | Very likely (−2) | Dose-response gradient (+1) | ⊕⊕ Low ⊕ Very Low |
Very serious limitations (−2) | Very serious limitations (−2) | Very serious limitations (−2) | Very serious limitations (−2) | All plausible confounding increases confidence in estimate (+1) Other considerations (+1) |
|||
Resolution | |||||||
2 RCTs | No serious limitations | No serious limitations | Serious limitations (−1)b | No serious limitations | Undetected | – | ⊕⊕⊕ Moderate |
40 observational case series | Serious limitations (−1)a | No serious limitations | No serious limitations | No serious limitations | Undetected | – | ⊕⊕ Low |
Quality of life | |||||||
0 studies | – | – | – | – | – | – | – |
Mortality | |||||||
2 RCTs | No serious limitations | No serious limitations | No serious limitations | Very serious limitations (−2)c | Undetected | ⊕⊕ Low | |
40 observational case series | Serious limitations (−1)a | No serious limitations | No serious limitations | No serious limitations | Undetected | – | ⊕⊕ Low |
Adverse events | |||||||
2 RCTs | Serious limitations (−1)d | No serious limitations | No serious limitations | Serious limitations (−1)c | Undetected | – | ⊕⊕ Low |
40 observational case series | Serious limitations (−1)a | No serious limitations | No serious limitations | No serious limitations | Undetected | – | ⊕⊕ Low |
Abbreviations: GRADE, Grading of Recommendations Assessment, Development, and Evaluation; RCT, randomized controlled trial.
Observational uncontrolled, mostly retrospective case series.
Most fecal microbiota therapy in Ontario is via enema. Studies published to date mostly use colonoscopy and nasoduodenal or nasogastric tube.
Optimal information size not met. Wide confidence intervals.
Lack of long-term follow-up in RCTs (up to 10 weeks).